SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

CARE revises ratings assigned to Orchid Pharma’s bank facilities

18 Apr 2017 Evaluate

Credit rating agency, Credit Analysis & Research (CARE) has revised rating assigned to Orchid Pharma’s long term bank facilities worth Rs 2687.49 crore to ‘D’ from ‘B-’. The rating agency has also revised rating assigned to company’s short term bank facilities worth Rs 498.50 crore to ‘D’ from ‘A4’. The revision in ratings assigned to the bank facilities of Orchid Pharma takes into account instances of delays in debt servicing.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.

Orchid Pharma Share Price

565.80 0.20 (0.04%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×